Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy.
The medical treatment of chronic heart failure has undergone a dramatic transition in the past decade. Short-term approaches for altering hemodynamics have given way to long-term, reparative strategies, including beta-adrenergic receptor (betaAR) blockade. This was once viewed as counterintuitive, because acute administration causes myocardial depression. Cardiac myocytes from failing hearts show changes in betaAR signaling and excitation-contraction coupling that can impair cardiac contractility, but the role of these abnormalities in the progression of heart failure is controversial. We therefore tested the impact of different manipulations that increase contractility on the progression of cardiac dysfunction in a mouse model of hypertrophic cardiomyopathy. High-level overexpression of the beta(2)AR caused rapidly progressive cardiac failure in this model. In contrast, phospholamban ablation prevented systolic dysfunction and exercise intolerance, but not hypertrophy, in hypertrophic cardiomyopathy mice. Cardiac expression of a peptide inhibitor of the betaAR kinase 1 not only prevented systolic dysfunction and exercise intolerance but also decreased cardiac remodeling and hypertrophic gene expression. These three manipulations of cardiac contractility had distinct effects on disease progression, suggesting that selective modulation of particular aspects of betaAR signaling or excitation-contraction coupling can provide therapeutic benefit.
Freeman
K
K
Department of Molecular, Cellular, and Developmental Biology, University of Colorado, Boulder, CO 80309-0347, USA.
Lerman
I
I
Kranias
E G
EG
Bohlmeyer
T
T
Bristow
M R
MR
Lefkowitz
R J
RJ
Iaccarino
G
G
Koch
W J
WJ
Leinwand
L A
LA
D000199:Actins / Q000235:genetics; D000818:Animals; D009320:Atrial Natriuretic Factor / Q000235:genetics; D015415:Biomarkers; D002118:Calcium / Q000378:metabolism; D020013:Calcium Signaling; D002135:Calcium-Binding Proteins / Q000378:metabolism; D002312:Cardiomyopathy, Hypertrophic / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology*; D017868:Cyclic AMP-Dependent Protein Kinases / Q000037:antagonists & inhibitors / Q000235:genetics; D004195:Disease Models, Animal; D018450:Disease Progression; D005260:Female; D015870:Gene Expression; D006333:Heart Failure / Q000473:pathology; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D009043:Motor Activity; D009206:Myocardium / Q000378:metabolism / Q000473:pathology; D018995:Myosin Heavy Chains / Q000235:genetics; D018343:Receptors, Adrenergic, beta-2 / Q000235:genetics / Q000378:metabolism*; D051552:beta-Adrenergic Receptor Kinases; D000099211:Phospholamban
D000199:Actins; D009320:Atrial Natriuretic Factor; D015415:Biomarkers; D002118:Calcium; D002135:Calcium-Binding Proteins; D017868:Cyclic AMP-Dependent Protein Kinases; D018995:Myosin Heavy Chains; D018343:Receptors, Adrenergic, beta-2; D051552:beta-Adrenergic Receptor Kinases; D000099211:Phospholamban